• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Cochlear lands breakthrough FDA win for Nucleus Hybrid L24 hearing aid

Cochlear lands breakthrough FDA win for Nucleus Hybrid L24 hearing aid

March 20, 2014 By Arezu Sarvestani

Cochlear lands breakthrough FDA win for Nucleus Hybrid L24 hearing aid

UPDATED March 21, 2013 with comments from Cochlear Americas president, principal investigator.

Australia’s Cochlear Ltd. (ASX:COH) won breakthrough FDA approval today for its Nucleus Hybrid L24 implantable hearing system, the 1st device of its kind on the U.S. market.

The technology is the 1st implantable hearing aid approved for adults who can still hear low-frequency sounds but can’t make out high-frequency sounds in either ear due to damage in the inner ear.

"People with severe or profound sensorineural hearing loss of high-frequency sounds may have difficulty hearing faint sounds, understanding people with higher-pitched voices, hearing certain speech sounds, and, in some cases, hearing high-pitched emergency vehicle sirens or common safety alarms, such as smoke detectors," according to the FDA memo.

The Nucleus Hybrid L24 combines hearing aid and cochlear implant technology, featuring an external microphone and speech processor as well as implanted electrodes to create "a sense of sound that the user learns to associate with the mid- and high-frequency sounds they remember."

Approval was based partly on results from a 50-patient clinical trial in patients, most of which reported significant improvements in word and sentence hearing 6 months following implantation of the technology. Nearly 70% of patients, however, also reported adverse events, including low-frequency hearing loss, tinnitus, electrode malfunction and dizziness, the FDA said. 6 patients underwent revision surgery to replace the Nucleus Hybrid L24 with a standard cochlear implant.

"The launch of the 1st-of-its-kind Nucleus Hybrid system means that we have the opportunity to give people back what they’ve been missing with their hearing aids," Cochlear Americas president Chris Smith said in prepared remarks. "By amplifying low-frequency hearing and restoring access to high-frequency hearing, this innovative new hybrid hearing solution will help people regain the sounds of life that had previously been lost, and ultimately empower them to connect with others and live a full life. We look forward to expanding access to hearing and instilling hope in those who may be suffering without an effective solution."

"The clinical data supporting the FDA approval of the Nucleus Hybrid System is very encouraging as it shows superior hearing performance compared to acoustic amplification alone," added lead investigator Dr. Thomas Roland Jr. of the NYU Langone Medical Center in New York. "What this means is that we now have an effective solution that offers hybrid hearing to patients who may benefit from both electric and acoustic amplification, and that most patients will likely be very satisfied with the results."

The FDA win comes about 4 months after the agency’s Ear, Nose & Throat Devices advisory panel voted in favor of approval. That panel also considered a 66-patient clinical trial in which patients similarly reported "significantly improved" speech perception, sound quality and quality of life compared with preoperative hearing aids.

The company is on a roll, having just won FDA 510(k) clearance for its Baha 4 Attract device, a bone conduction hearing system that uses a series of magnets to conduct sound. Cochlear in August won European approval for its Nucleus 6, the smallest behind-the-ear sound processor to hit European markets at the time.

COH shares closed on the Australian market today at $56.58, down 1% on the day.

Filed Under: Food & Drug Administration (FDA), News Well, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: Cochlear Americas, Cochlear Ltd., Hearing

More recent news

  • Cognixion, Blackrock Neurotech ink distro deal for BCI tech
  • AdvaMed calls for medtech tariff exemptions at Senate hearing
  • GE HealthCare, Raydiant Oximetry partner on fetal oxygen saturation tech
  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy